etrasimod
| SMILES | OC(=O)C[C@H]1CCc2c1[nH]c1c2cc(cc1)OCc1ccc(c(c1)C(F)(F)F)C1CCCC1 |
| InChIKey | MVGWUTBTXDYMND-QGZVFWFLSA-N |
Chemical properties
| Hydrogen bond acceptors | 2 |
| Hydrogen bond donors | 2 |
| Rotatable bonds | 6 |
| Molecular weight (Da) | 457.2 |
Drug properties
| Molecular type | Small molecule |
| Physiological/Surrogate | Surrogate |
| Approved drug | Yes |
Database connections
Bioactivities
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
| S1P1 | S1PR1 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.725000000000001 | 8.73 | 8.73 | Guide to Pharmacology |
| S1P4 | S1PR4 | Human | Lysophospholipid (S1P) | A | pEC50 | 6.83 | 6.83 | 6.83 | Guide to Pharmacology |
| S1P5 | S1PR5 | Human | Lysophospholipid (S1P) | A | pEC50 | 7.61 | 7.61 | 7.61 | Guide to Pharmacology |
| S1P1 | W5VNF7 | Dog | Lysophospholipid (S1P) | A | pEC50 | 9.47 | 9.47 | 9.47 | ChEMBL |
| S1P1 | H9EUW9 | Rhesus macaque | Lysophospholipid (S1P) | A | pEC50 | 9.49 | 9.49 | 9.49 | ChEMBL |
| S1P1 | S1PR1 | Mouse | Lysophospholipid (S1P) | A | pEC50 | 9.36 | 9.36 | 9.36 | ChEMBL |
| A3 | AA3R | Human | Adenosine | A | pIC50 | 5.48 | 5.48 | 5.48 | ChEMBL |
| S1P1 | S1PR1 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.21 | 9.3 | 10.4 | ChEMBL |
| S1P1 | S1PR1 | Human | Lysophospholipid (S1P) | A | pIC50 | 8.73 | 8.73 | 8.73 | ChEMBL |
| S1P4 | S1PR4 | Human | Lysophospholipid (S1P) | A | pEC50 | 6.83 | 6.83 | 6.83 | ChEMBL |
| S1P5 | S1PR5 | Human | Lysophospholipid (S1P) | A | pEC50 | 7.61 | 7.61 | 7.61 | ChEMBL |
| S1P1 | S1PR1 | Rat | Lysophospholipid (S1P) | A | pEC50 | 9.49 | 9.49 | 9.49 | ChEMBL |